Niagen Bioscience (historically known as ChromaDex Corporation) maintains a market capitalization fluctuating around $190 million to $250 million on public equity markets. As a pioneer in bioscience research and the commercialization of nicotinamide riboside dietary ingredients, the enterprise's corporate valuation shifts continuously during active trading sessions based on quarterly revenue growth, global distribution agreements, intellectual property assets, and investor sentiment across the biotechnology sector.